Replacing a solid tumor biopsy may be a reality. The baby can be sequenced at birth so that it can help lead a healthy lifestyle. For each manifestation of the disease, genetic testing plays a vital role for more accurate tests using the best biomarkers that exactly match the actual genetic material. The promise of personalized medicine can only be achieved through better diagnostics to develop safer and more effective treatments.
Concomitant diagnostics are IVD tests or analyzes designed to extract the genetic and genomic characteristics of a patient, which help physicians and doctors make better decisions for treating a particular indication. The US FDA defines it as a medical device that identifies or defines a condition for a therapeutic product. This helps ensure the most likely and successful therapeutic intervention, obtaining information through patient diagnosis. Many pharmaceutical and biotech companies have focused on cost management through the development of co-morbid diagnostics, as well as the targeted therapeutic area. To this end, in partnership with diagnostic firms, significant growth has taken place in order to develop and produce diagnostics that are more targeted and effective.
How did companies visualize opportunities in the development of therapy using concomitant diagnostics?
The first companion diagnostics was launched in the 1980s. His future success is mainly related to sequencing and the development of personalized medicine. In 2014, Illumina introduced the HiSeq X Ten sequencing system, which reduced the cost of sequencing the human genome to $ 1,000 and was acceptable to many families. Over the course of a year, the system could transmit almost 18,000 human genomes. Concomitant diagnostics is mainly used in oncology, for scanning samples of tumors from a large population. Other indications, such as treatment of cystic fibrosis, are also in the spotlight.
One of the key factors is the financial environment for diagnostic and research tool companies. Recently, Qiagen collaborated with Centogene to increase the clinical prediction of rare diseases. Inotrem collaborated with Roche Diagnostics to develop a companion diagnostic test in the field of septic shock. Despite the fact that there was a lot of cooperation, the success rate was low. For example, Gefitinib, sold by AstraZeneca, had a disappointing result (the drug did not work on 90% of patients and the results of the waves). Since then, there have been several launches of new treatments. is FoundationOne CDx, Foundation Medicine, a genomic mapping test for all solid tumors.
Can Companion Diagnostics be successful in the near future?
A market research firm's report estimated the CAGR at 35% for the global exchange statistics market and predicted that by 2022 the market would be worth about $ 26 billion. USA. Due to the growing demand for personalized drugs and awareness among the population of the same, the industry has recorded a huge increase. Growing incidences of cancer worldwide have also been a major driver for this market. Due to the fact that companies are expanding their cooperation to improve biomarkers and diagnostics, there are great opportunities for application in indications other than cancer, for example, in cardiovascular, neurological diseases, etc.
Some of the main obstacles to this market are the high costs associated with the development of therapeutic and diagnostic tests. With a high risk of failure in clinical trials, many companies prefer partnerships to minimize their failure rates. Cost recovery issues in different countries also impede the growth of this market.
